Diy13/iStock via Getty Images
Traus Pharma shares (Nasdaq:herb) rose 24% in post-market trading on Friday thanks to encouraging results from a phase 1 study of the company’s drug Tivoxavir Marboxil in treating H5N1 avian influenza.
The study showed a single dose of
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2184256360/image_2184256360.jpg?io=getty-c-w750
Source link